文献速递银屑病与炎症性皮肤病

依奇珠单抗每2周持续给药与推荐剂量在中重度斑块状银屑病第12周sPGA>1患者中的长期疗效间接比较

An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12.
PubMed 文献 · Br J Dermatol · 2019-12-08

本研究对IXORA-P研究中第12周sPGA>1且持续每2周(Q2W)给药的银屑病患者,与UNCOVER-1/2/3整合数据中按标签剂量(Q2W/Q4W)给药的患者进行间接比较,以持续Q4W组为共同对照。

要点

  • 第12周sPGA>1者继续Q2W至52周,sPGA≤1达标率64% vs 标签剂量36%。
  • IXORA-P中第12周sPGA≤1与>1两组间安全性事件频率无临床意义差异。
  • 第12周未达clear/almost clear者,延长Q2W或可提高第52周皮损清除率。

核心结论

  • IXORA-P研究中第12周sPGA≤1与sPGA>1两组间安全性事件频率无临床意义差异。

研究设计与样本

  • 间接比较:IXORA-P研究中第12周sPGA>1并持续Q2W给药至52周的疗效,与UNCOVER-1、UNCOVER-2、UNCOVER-3整合数据中Q2W/Q4W给药的疗效进行比较。
  • 以持续Q4W剂量组作为共同对照,该组在各研究间结果可比。

主要发现

  • IXORA-P中第12周sPGA>1者持续Q2W组第52周sPGA≤1达标率为64%。
  • UNCOVER整合数据中第12周sPGA>1者Q2W/Q4W组第52周sPGA≤1达标率为36%。

关键数值与推荐

  • 第12周sPGA>1且持续Q2W至52周者,第52周sPGA≤1为64%。

临床怎么用

  • 对第12周未达sPGA≤1的中重度斑块状银屑病患者,可考虑延长Q2W给药以提升第52周皮损清除率。
  • 延长Q2W给药时需结合患者个体情况评估获益与安全性。

局限性

  • 为间接比较而非头对头随机对照研究。
  • 原文未报告间接比较的置信区间及混杂因素调整细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term efficacy and safety of ixekizumab [160 mg at week 0, then 80 mg every 2 weeks (Q2W) for 12 weeks, followed by every 4 weeks (Q4W) thereafter (i.e. Q2W/Q4W), which is the labelled psoriasis dosing where approved, except in Japan] have been established for the treatment of adults with moderate-to-severe plaque psoriasis. However, some patients may benefit from remaining on Q2W dosing beyond 12 weeks. METHODS: Among patients who had static Physician's Global Assessment (sPGA) > 1 at week 12, efficacy through week 52 of continuous Q2W dosing in the IXORA-P study was compared indirectly with Q2W/Q4W in the integrated data from the UNCOVER-1, UNCOVER-2 and UNCOVER-3 studies. The continuous Q4W dose group, which had comparable results across studies, was used as the common comparator. RESULTS: In the IXORA-P study, among patients with sPGA > 1 at week 12, 64% of patients in the continuous Q2W group achieved sPGA ≤ 1 at week 52, which was statistically significantly higher than the 36% of patients with sPGA > 1 in the Q2W/Q4W group based on the integrated data from the UNCOVER studies (P = 0·0007). There were no clinically meaningful differences in frequencies of safety events between patients with sPGA ≤ 1 and patients with sPGA > 1 at week 12 in the IXORA-P study. CONCLUSIONS: Among patients who did not have clear or almost clear skin at week 12, nearly 30% more patients who were treated continuously with ixekizumab Q2W in IXORA-P had clear or almost clear skin at week 52 when compared indirectly with those who were treated using the labelled psoriasis dosing in integrated UNCOVER studies. What's already known about this topic? Most patients with moderate-to-severe psoriasis who were given the labelled psoriasis dosing of ixekizumab [160-mg loading dose at week 0, 80 mg every 2 weeks (Q2W) through week 12, and 80 mg every 4 weeks (QW4) thereafter] respond quickly with a high percentage of skin clearance. Additionally, patients who achieve static Physician's Global Assessment (sPGA) ≤ 1 by week 12 tend to maintain this response, even after switching to Q4W. What does this study add? Here, we assessed whether patients with sPGA > 1 at week 12 benefited from receiving more frequent dosing beyond the first 12 weeks. The results showed that Q2W dosing beyond 12 weeks resulted in more patients achieving sPGA ≤ 1 by week 52 than the labelled psoriasis dosing among patients with sPGA > 1 at week 12.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Papp K, Maari C, Cauthen A, et al. An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12. Br J Dermatol. 2019. PMID: 31545506. doi:10.1111/bjd.18550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。